• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Assessment of liver ability to biotransformation of antipyrine in uraemic patients on regular peritoneal dialysis treatment.

作者信息

Grzegorzewska A, Lowicki Z, Chmara E, Mrozikiewicz A, Baczyk K

机构信息

Department of Nephrology, K. Marcinkowki Academy of Medicine, Poznań, Poland.

出版信息

Int Urol Nephrol. 1989;21(5):541-5. doi: 10.1007/BF02549593.

DOI:10.1007/BF02549593
PMID:2613484
Abstract

It was the aim of this work to establish whether biotransformation of drugs by the liver expressed by antipyrine kinetics is disturbed in peritoneally dialysed patients with end-stage renal failure. The investigations were carried out in 10 uraemic patients using the antipyrine test and comparing the parameters of antipyrine kinetics with those obtained in 13 healthy persons. Our results indicate that in uraemic patients on regular peritoneal dialysis treatment antipyrine kinetics are generally in the normal range, suggesting the microsomal content of cytochrome P-450 being not evidently reduced.

摘要

相似文献

1
Assessment of liver ability to biotransformation of antipyrine in uraemic patients on regular peritoneal dialysis treatment.
Int Urol Nephrol. 1989;21(5):541-5. doi: 10.1007/BF02549593.
2
[Evaluation of the capacity of the liver for phenazone biotransformation in patients with uremia on peritoneal dialysis].
Pol Tyg Lek. 1990;45(16-18):339-41.
3
[An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].[基于唾液中安替比林消除率评估犊牛肝脏生物转化活性的尝试]
Pol Arch Weter. 1991;31(3-4):65-71.
4
Effects of glucose-containing peritoneal-dialysis solutions on rates of lipogenesis in vivo in the liver, brown and white adipose tissue of chronic uraemic rats.含葡萄糖腹膜透析液对慢性尿毒症大鼠肝脏、棕色和白色脂肪组织体内脂肪生成率的影响。
Biochem J. 1983 Aug 15;214(2):459-64. doi: 10.1042/bj2140459.
5
[Evaluation of metabolic efficiency of the liver in patients with psoriasis by the antipyrine test].
Przegl Dermatol. 1990 Sep-Oct;77(5):301-6.
6
In vitro hepatic oxidative metabolism of antipyrine, phenytoin and phenylbutazone in uraemic rabbits.
J Pharm Pharmacol. 1980 Feb;32(2):135-6. doi: 10.1111/j.2042-7158.1980.tb12870.x.
7
In-vitro biotransformation of antipyrine, lignocaine and propranolol in the liver of rats with turpentine-induced inflammation.
J Pharm Pharmacol. 1987 Nov;39(11):883-6. doi: 10.1111/j.2042-7158.1987.tb03122.x.
8
Monthly variations in the pharmacokinetics of antipyrine in calves.
Arch Vet Pol. 1992;32(3-4):113-8.
9
Immunopathological changes in a uraemic rat model for peritoneal dialysis.腹膜透析尿毒症大鼠模型的免疫病理变化
Nephrol Dial Transplant. 2005 Jul;20(7):1350-61. doi: 10.1093/ndt/gfh835. Epub 2005 Apr 19.
10
[Pharmacokinetics of antipyrine in viral and alcoholic lesions of the liver].
Klin Med (Mosk). 1989 Feb;67(2):87-9.

本文引用的文献

1
The use of antipyrine in the measurement of total body water in man.安替比林在人体全身水含量测量中的应用。
J Biol Chem. 1949 May;179(1):31-42.
2
The estimation of antipyrine in biological materials.生物材料中安替比林的测定。
J Biol Chem. 1949 May;179(1):25-9.
3
The fate of antipyrine in man.安替比林在人体内的代谢情况。
J Pharmacol Exp Ther. 1950 Jan;98(1):97-104.
4
Effect of azotemia upon the action of intravenous barbiturate anesthesia.氮质血症对静脉注射巴比妥类麻醉作用的影响。
Anesthesiology. 1954 Jul;15(4):333-46. doi: 10.1097/00000542-195407000-00001.
5
Cefsulodin kinetics in renal impairment.头孢磺啶在肾功能损害中的动力学
Clin Pharmacol Ther. 1982 May;31(5):602-8. doi: 10.1038/clpt.1982.84.
6
Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure.正常受试者和慢性肾衰竭患者D-木糖吸收的动力学分析。
J Lab Clin Med. 1983 Mar;101(3):496-506.
7
[Effect of labetalol on antipyrine metabolism in the liver].
Pol Arch Med Wewn. 1984 Mar;71(3):149-55.
8
[Pharmacokinetics of phenazone as an indicator of the metabolic capacity of the liver in patients with hyperthyroidism].
Pol Tyg Lek. 1983;38(20-21):643-5.
9
Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man.肝脏药物氧化机制及其与人氧化速率个体差异的关系。
Ann N Y Acad Sci. 1971 Jul 6;179:411-20. doi: 10.1111/j.1749-6632.1971.tb46918.x.
10
Rate of drug metabolism in obese volunteers before and during starvation and in azotemic patients.肥胖志愿者在饥饿前、饥饿期间以及氮质血症患者的药物代谢率。
Metabolism. 1969 Mar;18(3):209-13. doi: 10.1016/0026-0495(69)90040-7.